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ABSTRACT
ObjeCtive
To investigate the benefits and costs of implementing 
non-invasive prenatal testing (NIPT) for Down’s 
syndrome into the NHS maternity care pathway.
Design
Prospective cohort study.
setting
Eight maternity units across the United Kingdom 
between 1 November 2013 and 28 February 2015.
PartiCiPants
All pregnant women with a current Down’s syndrome 
risk on screening of at least 1/1000.
Main OutCOMe Measures
Outcomes were uptake of NIPT, number of cases of 
Down’s syndrome detected, invasive tests performed, 
and miscarriages avoided. Pregnancy outcomes and 
costs associated with implementation of NIPT, 
compared with current screening, were determined 
using study data on NIPT uptake and invasive testing in 
combination with national datasets.
results
NIPT was prospectively offered to 3175 pregnant 
women. In 934 women with a Down’s syndrome risk 
greater than 1/150, 695 (74.4%) chose NIPT, 166 
(17.8%) chose invasive testing, and 73 (7.8%) declined 
further testing. Of 2241 women with risks between 
1/151 and 1/1000, 1799 (80.3%) chose NIPT. Of 71 
pregnancies with a confirmed diagnosis of Down’s 
syndrome, 13/42 (31%) with the diagnosis after NIPT 
and 2/29 (7%) after direct invasive testing continued, 
resulting in 12 live births. In an annual screening 
population of 698 500, offering NIPT as a contingent 
test to women with a Down’s syndrome screening risk 
of at least 1/150 would increase detection by 195 (95% 
uncertainty interval −34 to 480) cases with 3368 (2279 
to 4027) fewer invasive tests and 17 (7 to 30) fewer 
procedure related miscarriages, for a non-significant 
difference in total costs (£−46 000, £−1 802 000 to 
£2 661 000). The marginal cost of NIPT testing 
strategies versus current screening is very sensitive to 
NIPT costs; at a screening threshold of 1/150, NIPT 
would be cheaper than current screening if it cost less 
than £256. Lowering the risk threshold increases the 
number of Down’s syndrome cases detected and 
overall costs, while maintaining the reduction in 
invasive tests and procedure related miscarriages.
COnClusiOns
Implementation of NIPT as a contingent test within a 
public sector Down’s syndrome screening programme 
can improve quality of care, choices for women, and 
overall performance within the current budget. As 
some women use NIPT for information only, the Down’s 
syndrome live birth rate may not change significantly. 
Future research should consider NIPT uptake and 
informed decision making outside of a research 
setting.
Introduction
Non-invasive prenatal testing (NIPT), based on 
sequencing of cell-free DNA in maternal plasma, is a 
highly effective screening test for Down’s syndrome 
with sensitivities around 99% and false positive rates 
of less than 0.1%,1 in both high risk and general popu-
lations.2 3 NIPT can also screen for trisomies 13 and 18 
and sex chromosome aneuploidies, albeit with poorer 
performance.1 In the United States, widespread uptake 
of NIPT has significantly reduced rates of invasive test-
ing.4  NIPT is now available worldwide, but largely 
through private sector healthcare providers or partial 
self funding by women in public sector Down’s syn-
drome screening pathways in some European coun-
tries.5  Women and health professionals welcome the 
possibility of NIPT because of the potential for 
increased detection of Down’s syndrome pregnancies 
with a decreased need for invasive diagnostic testing 
and the associated iatrogenic miscarriages.6-8 However, 
implementation into public sector maternity care 
requires careful evaluation because of the likely changes 
to the care pathway, educational requirements, and 
WhAT IS AlReAdy knoWn on ThIS TopIC
Non-invasive prenatal testing (NIPT) based on analysis of cell-free DNA in maternal 
plasma is a highly accurate screening test for Down’s syndrome that is likely to be 
cost effective if offered as a contingent screening test
Although NIPT is increasingly available worldwide, access is primarily through the 
private sector
The costs and consequences of implementation of NIPT into public sector maternity 
care have not been assessed in a clinical setting
WhAT ThIS STudy AddS
NIPT can be provided effectively as part of a publicly funded national Down’s 
syndrome screening pathway
It will improve the performance of the programme without significantly increasing 
costs if offered as a contingent test at a risk threshold of 1/150
Uptake of NIPT by women is high, with some of them seeking information to prepare 
for the birth of a baby with Down’s syndrome
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potential effect on limited public sector resources. 
 Several studies have suggested that NIPT for Down’s syn-
drome as a contingent test is likely to be cost effective.9-22 
The available UK data describing uptake of NIPT come 
from two maternity units where the uptake of Down’s 
syndrome screening is much higher (98.2%) than the 
national average of 66% for both the first trimester com-
bined test and the second trimester quadruple test.23-25 
Little information from the United Kingdom or elsewhere 
describes uptake of NIPT in units with a wider range of 
screening uptakes that would be more compatible with 
the national average, and none describes costs as well as 
outcomes in a fully state funded healthcare setting. Many 
national and international bodies recommend the use 
of NIPT as a screening test for women at increased risk 
of Down’s syndrome;26-28  although some suggest it 
should be available to all women,29  30  the current high 
cost of NIPT is likely to preclude this in most public 
 sector screening programmes.9 31
The objective of this study was to investigate the 
potential costs and consequences of introducing NIPT 
in our public sector Down’s syndrome screening path-
way as a further screening test contingent on the risk 
generated by current screening, to help to inform the 
UK National Screening Committee’s decisions on imple-
mentation. We developed health economic models that 
were informed by national datasets and data from our 
cohort study, which provided information on uptake of 
Down’s syndrome screening, NIPT, and invasive test-
ing, as well as pregnancy outcomes and costs. We chose 
to introduce NIPT as a contingent test for women with a 
current risk on screening of at least 1/1000 to allow eval-
uation of a range of potentially affordable policies and 
to avoid any possible reduction in detection of Down’s 
syndrome as suggested by previous studies.9 The cur-
rent cost of NIPT precluded further lowering of the risk 
threshold in this study or offering NIPT to all women.
Methods
study design and population
This RAPID (Reliable, Accurate Prenatal, non-Invasive 
Diagnosis) research programme study was a prospec-
tive cohort study performed in eight NHS hospitals 
between 1 November 2013 and 28 February 2015. How-
ever, it includes only cases reported over a 15 month 
period as the study was suspended from 26 September 
2014 to 10 October 2014 owing to failure and subsequent 
unavailability of Illumina library preparation kits. NIPT 
was not available through NHS pathways in the mater-
nity units participating in the study, but it was available 
through the private sector across the United Kingdom at 
the time the study was performed. In line with current 
clinical practice, all pregnant women attending for 
antenatal care were offered screening for Down’s syn-
drome by the combined test if they booked before 14 
weeks’ gestation or the quadruple test if they booked 
later, up to 20 weeks. Women aged over 16 years accept-
ing combined or quadruple testing with a subsequent 
risk of at least 1/1000 were eligible for the study. Women 
with a risk above 1/150, the current risk threshold for 
offering invasive diagnostic testing, were prospectively 
offered invasive testing or NIPT as a contingent test and 
could choose one of these options or no further testing 
(fig 1 ). If the risk was between 1/151 and 1/1000, they 
were offered NIPT. Women declining screening and 
those with a risk below 1/1000, with multiple pregnan-
cies, or who could not understand the participant 
 information were excluded. Figure 1  shows the study 
pathway, and a detailed protocol has been published.32 
Participating maternity units had populations of preg-
nant women from a range of social and ethnic groups, 
with variable uptake of screening, and delivery of the 
screening pathway through either one stop or two stop 
clinics (see table 1 for details). Before starting the study, 
researchers trained local midwives by using materials 
developed on the basis of previous work.8 33
During the study, all pregnant women were sent 
information on NIPT with their booking information 
(appendix A). While booking women for maternity 
care, midwives briefly discussed NIPT and obtained 
permission to contact the woman if her Down’s syn-
drome screening result was a risk of at least 1/1000. 
Women with a risk of 1/1000 or greater were given 
more detailed participant information (appendix B) 
and offered an appointment with a healthcare profes-
sional trained to discuss the benefits and limitations 
of NIPT before giving written consent to participate in 
the study. At sites with one stop Down’s syndrome 
screening, this offer of NIPT was usually made on the 
same day that screening was performed. At other sites, 
women were contacted by phone and offered an 
appointment to discuss NIPT. For those who could not 
be contacted, two further attempts were made before 
they were excluded from the study. Women with a risk 
of at least 1/150 and a nuchal translucency measure-
ment of at least 3.5 mm, or sonographic abnormalities, 
were offered a choice between NIPT (including testing 
for Turner’s syndrome), invasive prenatal diagnosis, 
or neither. All women consenting to NIPT had blood 
taken for sequencing of cell-free DNA in our public 
sector accredited genetics laboratory, using a HiSeq 
2500 (Illumina Inc) and locally developed protocols 
and bioinformatics pipeline.34 Analysis of chromo-
somes 21, 18, and 13 was performed in all cases; the X 
chromosome was included in the analysis only for 
women at high risk with a nuchal translucency mea-
surement of at least 3.5 mm or sonographic abnormal-
ities. NIPT results were reported as “highly unlikely to 
be affected” or “predicted to be affected”. We aimed to 
report NIPT results within 10 days of blood draw. All 
women with inconclusive or failed tests were offered 
repeat NIPT. Those with a Down’s syndrome screening 
risk of at least 1/150 were offered the choice of repeat 
NIPT or invasive testing. Women with a “predicted to 
be affected” result were advised that although the 
NIPT result was positive, it is not diagnostic and inva-
sive testing for confirmation is recommended. Preg-
nancy outcomes were ascertained from local unit 
records or the women themselves. To determine any 
change in women’s choices, we compared uptake of 
Down’s syndrome screening and uptake of direct inva-
sive testing in women with a risk of at least 1/150 for 
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the period 1 November 2011 to 31 October 2012, before 
the availability of NIPT in the United Kingdom, and 
during the study.
sample size calculation
The overall study sample size was justified on the preci-
sion achieved for the differences in uptake of testing, 
overall detection rate, and false positive rate between 
the existing Down’s syndrome screening pathway and 
the new contingent NIPT pathway. Initial estimates 
indicated that a screened sample of 25 000 would 
enable a reduction in false positive rate with the contin-
gent pathway compared with the existing pathway to be 
estimated to within ±0.2%.32
Measuring costs and consequences
We did a cost consequence analysis of NIPT as contin-
gent testing from the perspective of the UK National 
Screening Committee, as this committee will advise 
government ministers whether to implement NIPT into 
NHS care.35  We chose this form of economic evaluation 
because there are several relevant outcome measures 
(number of invasive tests, Down’s syndrome cases 
detected, invasive testing related miscarriages). Quality 
adjusted life years (QALYs) are not commonly used in 
economic evaluations of prenatal testing for Down’s 
syndrome, and we did not use them here. We therefore 
limited the analysis to the costs of the screening path-
way (screening, NIPT, and diagnostic testing, including 
NIPT study and DSS information sent by mail
Booking appointment -discussion and oer of DSS and NIPT study (n=40 527)
Risk ≥1/150 (n=958*)Risk 1/151-1/1000 (n=2651)Risk <1/1000 (n=27 181)
Predicted to be
aected (n=59¶)
Oer diagnosis
(n=57; 2 miscarriage)
No further
testing (n=20)
Repeat NIPT (n=63) Amnio/CVS
(n=8**; 1 T13)
Lost to
follow-up (n=3)
Normal (n=106) Abnormal (n=58)
Aneuploidy highly
unlikely (n=2342)
NIPT inconclusive
or failed (n=94)
Procedure successful (n=164) Miscarriage (n=1)
Discuss options
with parents
Discuss options
with parents
Failed (n=10)
Normal (n=5)
Predicted to be
aected (n=2¶)
Continue
(n=2; 2 T21 live births)
Miscarriage (n=1; 1 T18)Termination (n=55;
27 T21, 16 T18, 6 T13,
1 triploidy, 5 45,XO)
Termination
(n=35; 29 T21, 4 T18,
1 T21/T18,1 45,XO)
Normal (n=51)
Abnormal (n=42)
Amnio centesis/CVS
declined (n=10)
Amnio centesis/CVS
(n=47)
Screening declined  (n=9737)Screening accepted (n=30 790)
Oer NIPT or amnio/CVS (n=934*)Oer NIPT (n=2241)
DSS appointment-initial screening tests
Amnio/CVS (n=166§)Further testing declined (n=73†)
Continue (n=8)
Continue (n=7)
Termination
(n=2;1 T21, 1 T18)
Neonatal death (1 T13)Intrauterine death (1 T21)Live birth (6 T21)
Live birth
(n=4; 4 T21)
Miscarriage
(n=3; 2 T21, 1 T18)
NIPT performed (n=2493‡)NIPT declined (n=442†)
Fig 1 | Flowchart showing numbers of women recruited and outcomes. Cvs=chorionic villus sampling; Dss=Down’s syndrome screening; niPt=non-
invasive prenatal testing; t13=trisomy 13; t18=trisomy 18; t21=trisomy 21. *including 15 women with risk ≥1/150 for t13/t18 and risk 1/151-1/1000 for t21. 
†some women underwent Dss and declined further testing but were known to have had niPt in private sector (n=37). ‡One additional woman accepted 
niPt but no blood sample was obtained. §One procedure was not possible. ¶two women initially had inconclusive niPt results but were positive on 
repeat testing; these are included in inconclusive/failed pathway and also predicted to be affected pathway. **includes one case (t13) that had 
amniocentesis later in pregnancy after detection of fetal abnormalities
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sampling, laboratory testing, and feeding back the 
results). Costs were expressed in 2012/13 UK£; the time 
horizon was the duration of pregnancy, so discounting 
was unnecessary. We developed a decision tree (fig 2) 
for four different screening pathways (current pathway 
and NIPT as a contingent screening test for women with 
a screening risk of ≥1/150, ≥1/500, and ≥1/1000) and 
populated it with data from the cohort study and other 
sources. In our study, women with a risk of at least 1/150 
could choose to go directly to invasive testing, and we 
included three additional scenarios in which invasive 
testing was allowed only after a positive NIPT result. 
This yields a total of seven testing strategies being com-
pared. Although NIPT may have a role in detecting other 
trisomies, the overarching aim of the RAPID evaluation 
study was to evaluate NIPT for Down’s syndrome. For 
the economic analysis, we therefore focused on the 
Down’s syndrome screening pathway only and did not 
include other trisomies, even though women were 
offered screening for trisomies 13 and 18 in some clinics. 
Appendix C gives further details about the cost conse-
quences analysis.
Model inputs
We populated the decision tree by using two datasets 
(table 2). The first was based predominantly on data 
from the RAPID study. The second was based 
 predominantly on national data, using data from the 
RAPID study mainly to quantify test uptake behaviours 
associated with NIPT.
RAPID data—We used data from the study to assess 
the uptake of screening, uptake of NIPT and invasive 
testing, and test outcomes. We assessed the uptake of 
screening, screening test results, and uptake of invasive 
testing in the current pathway by using a historical 
dataset collected retrospectively in 2011-12 in the same 
clinics that were involved in the RAPID study but before 
NIPT was available in the United Kingdom. Uptake of 
screening was slightly higher before NIPT was offered 
than during the RAPID study (78.7% v 76.0%), possibly 
because some women had NIPT in the private sector 
and subsequently opted out of the national programme. 
In this analysis, we therefore assumed that this 
decrease in uptake of screening was unrelated to the 
RAPID study, so we used the same uptake percentage as 
in the current programme (78.7%). As the RAPID data 
are based on relatively small numbers, data on uptake 
of NIPT, invasive testing, and the remaining test out-
comes are based on RAPID data, but these were 
adjusted to account for the national prevalence of 
Down’s syndrome and maternal age distributions in 
England and Wales. This enabled valid comparison of 
different contingent screening strategies against a com-
mon underlying population (see appendices C and D for 
table 1 | Details of women booked, uptake of Down’s syndrome screening, non-invasive prenatal testing, and invasive prenatal diagnosis before and 
during study for all eight participating maternity units. values are numbers (percentages)
Maternity units*
totaluClH† QHr sgH* sal PaHs taY QCCH WHit
november 2011 to October 2012
Total booked 6456 11 669 6179 3057 6541 3666 5300 5066 47 934
DS screening uptake 5647 (87.5) 9712 (83.2) 5670 (91.8) 1390 (45.5) 4424 (67.6) 2759 (75.3) 4555 (85.9) 3575 (70.6) 37 732 (78.7)
Risk ≥1/150 216 (3.8) 242 (2.5) 164 (2.9) 29 (2.1) 128 (2.9) 98 (3.6) 121 (2.7) 113 (3.2) 1111 (2.9)
IPD uptake risk ≥1/150 153 (71) 99 (41) 116 (71) 17 (59) 80 (63) 50 (51) 78 (64) 74 (65) 667 (60.0)
Risk ≥1/150 declined all testing 63 (29) 143 (59) 48 (29) 12 (41) 48 (38) 48 (49) 43 (36) 39 (35) 444 (40.0)
study period (1 november 2013 to 28 February 2015)
Total booked 10 130 10 441 6011 2732 4117 1946 2988 2162 40 527
DS screening uptake 7497 (74.0) 8829 (84.6) 5436 (90.4) 1196 (43.8) 3015 (73.2) 1099 (56.5) 2138 (71.6) 1580 (73.1) 30 790 (76.0)
Total risk >1/1000 1199 (16.0) 735 (8.3) 611 (11.2) 129 (10.8) 354 (11.7) 76 (6.9) 297 (13.9) 208 (13.2) 3609 (11.7)
Total risk ≥1/150§ 289 (3.9) 216 (2.4) 142 (2.6) 31 (2.6) 92 (3.1) 36 (3.3) 96 (4.5) 56 (3.5) 958 (3.1)
Total risk 1/151-1/1000 910 (12.1) 519 (5.9) 469 (8.6) 98 (8.2) 262 (8.7) 40 (3.6) 201 (9.4) 152 (9.6) 2651 (8.6)
Eligible and offered risk >1/1000 1161 (15.5) 606 (6.9) 565 (10.4) 93 (7.8) 287 (9.5) 68 (6.2) 264 (12.3) 131 (8.3) 3175 (10.3)
Eligible and offered risk ≥1/150§ 281 (3.7) 212 (2.4) 138 (2.5) 29 (2.4) 90 (3.0) 36 (3.3) 92 (4.3) 56 (3.5) 934 (3.0)
Eligible and offered risk 
>1/151-1/1000
880 (11.7) 394 (4.5) 427 (7.9) 64 (5.4) 197 (6.5) 32 (2.9) 172 (8.0) 75 (4.7) 2241 (7.3)
IPD uptake risk ≥1/150 53 (19) 29 (14) 30 (22) 1 (3) 16 (18) 7 (19) 14 (15) 16 (29) 166 (17.8)
NIPT uptake risk ≥1/150 211 (75) 157 (74) 96 (70) 28 (97) 67 (74) 27 (75) 72 (78) 37 (66) 695 (74.4)
NIPT uptake risk 1/151-1/1000 803 (91.3) 280 (71) 360 (84) 49 (77) 107 (54) 20 (63) 129 (75) 51 (68) 1799 (80.3)
Declined all testing risk ≥1/150¶ 17 (6) 26 (12) 12 (9) 0 (0) 7 (8) 2 (6) 6 (7) 3 (5) 73 (7.8)
Declined all testing risk 
1/151-1/1000¶
77 (8.8) 114 (29) 67 (16) 15 (23) 90 (46) 12 (38) 43 (25) 24 (32) 442 (19.7)
DS=Down’s syndrome; IPD=invasive prenatal diagnosis; NIPT=non-invasive prenatal testing.
*UCLH=University College London Hospitals NHS Foundation Trust (started 1 Nov 2013); QHR=Barking, Havering and Redbridge University Hospitals NHS Trust (started 20 Jan 2014); SGH=St 
George's University Hospitals NHS Foundation Trust (started 3 Feb 2014); SAL=Salisbury NHS Foundation Trust (started 27 Jan 2014); PAHS=University Hospital Southampton NHS Foundation 
Trust (started 2 Jun 2014); TAY=NHS Tayside (started 4 Aug 2014); QCCH=Imperial College Healthcare NHS Trust (started 4 Aug 2014); WHIT=Whittington Hospital NHS Trust (started 11 Aug 
2014).
†One stop clinic (combined test results on day of scan so that NIPT is usually discussed at same visit as receiving DS screening result).
‡Staged start to recruitment and not all sites were recruiting until 11 Aug 2014, and study was suspended from 26 Sept 2014 to 10 Oct 2014 owing to failure and subsequent unavailability of 
library preparation kits. Thus, data presented here cover 15 month period.
§Including 15 women with risk ≥1/150 for trisomy 18/13 and risk 1/151-1/1000 for trisomy 21.
¶13 women with risk ≥1/150 and 24 women with risk 1/151-1000 underwent DS screening and declined NIPT (and IPD if high risk) but were known to have had NIPT in private sector (n=37).
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further details). For uptake of NIPT with a risk of Down’s 
syndrome of at least 1/150, the unadjusted figure from 
the RAPID study was 74.4% and the adjusted figure was 
72.5%. For uptake of NIPT with a risk of 1/151 to 1/1000, 
the unadjusted figure from the RAPID study was 80.3% 
and the adjusted figure was 70.5%. We used published 
estimates for the rate of miscarriage related to invasive 
testing.36
National data—We ran another version of the analy-
sis using predominantly national data to estimate costs 
on a national basis. We used national data to assess 
uptake of screening, screening test uptake in the cur-
rent pathway, screening test outcomes, and the invasive 
testing related miscarriage percentage. Data on uptake 
of NIPT and direct invasive testing and the remaining 
test outcomes were based on RAPID data, adjusted as 
described above, as these data are not available from 
national sources.
In our study, there were five discordant positive NIPT 
results, giving a positive predictive value of NIPT of 
90.9% for pregnancies with confirmed outcome, which is 
compatible with published data.1 2 We therefore used this 
value and varied the positive predictive value of NIPT in 
the sensitivity analysis. For the additional scenarios, in 
which we did not allow the option of direct invasive test-
ing for women with a risk of at least 1/150, we assumed 
that these women would have NIPT, which would give an 
overall uptake of NIPT in this group of 91%. In the RAPID 
study, several women at very high risk underwent inva-
sive testing directly, so the proportion of positive NIPT 
results was expected to be higher when these women 
were to undergo NIPT first. We estimated an average of 
7.9% positive NIPT results for this scenario.
We calculated the costs of Down’s syndrome screening, 
NIPT, and invasive testing on the basis of published 
sources and costs in participating centres (table 2).25 36-39
Current 
screening
Accept
screening
Decline
screening
Decline
screening
Risk<1/150
Risk<1/1000
Risk1/151
–1/1000
Risk≤1/150
Risk≤1/150
No invasive test
Invasive test
No invasive test
Invasive test
Fetal loss
No fetal loss
Fetal loss
No fetal loss
Termination
Continue pregnancy
Termination
Continue pregnancy
DS negative
DS positive
DS negative
DS positive
Pregnancy
NIPT contingent screening
Accept screening
No further testing
NIPT
No further testing
NIPT
NIPT negative
NIPT positive
No invasive test
Invasive test
Fetal loss
No fetal loss
Termination
Continue pregnancy
DS negative
DS positive
Fetal loss
No fetal loss
Termination
Continue pregnancy
DS negative
DS positive
NIPT negative
NIPT positive
Directly to invasive testing
Fig 2 | Decision tree depicting current screening pathway and new pathway using non-invasive prenatal testing (niPt) 
as contingent screening. in current screening pathway, women are offered invasive testing when their risk based on 
combined or quadruple test is ≥1/150. small risk of procedure related miscarriage exists, so some women at high risk 
decide not to undergo any further testing. if result of invasive test is positive, women can decide to terminate pregnancy. 
in niPt pathway, women are offered niPt test after high risk result (depending on threshold: ≥1/150, ≥1/500, or ≥1/1000) 
based on combined or quadruple test. Pathways for different thresholds are similar except for threshold risk at which niPt 
is offered as contingent screening. if niPt test result is positive, invasive test is offered to confirm diagnosis. some 
women with risk ≥1/150 after combined or quadruple test might decide to have invasive test directly and not have niPt 
first. Ds=Down’s syndrome
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Model outputs
Outcomes were the number of invasive tests performed, 
the number of Down’s syndrome positive cases detected 
(by NIPT or direct invasive testing and confirmed by 
invasive testing or at birth), and the number of invasive 
testing related miscarriages. Costs are presented sepa-
rately and combined for Down’s syndrome screening, 
NIPT, and invasive testing. Using the results of the 
study, we calculated estimates of the outcomes for NIPT 
in the Down’s syndrome screening programme, for a 
screening population of 698 500 annual live births in 
England and Wales.40 Detection of other trisomies is 
reported, but the economic analysis focuses on detec-
tion of Down’s syndrome to reflect the UK antenatal 
screening programme at the outset of the study.
Sensitivity analysis
We investigated uncertainty around model inputs by 
using one way sensitivity analysis and probabilistic 
sensitivity analysis (appendix C). In the one way sensi-
tivity analysis, we varied one parameter at a time over a 
plausible range to identify the maximum value at which 
introducing NIPT to the national screening programme 
would be cost neutral. We calculated costs in high risk 
pregnancies (≥1/150) for a range of uptake values for 
NIPT and direct invasive testing. We also calculated the 
incremental costs of implementing NIPT at a range of 
laboratory cost values (£50 to £500). In the probabilis-
tic sensitivity analysis, we produced 1000 simulations 
of the outputs, based on drawing random samples from 
the probability distributions of all input parameters. 
table 2 | input parameters for analysis of benefits and costs of non-invasive prenatal testing for aneuploidy as 
contingent test
Parameter raPiD data national data
screening test performed (%)
Combined test (first trimester) 88.5* 86.925
Quadruple test (second trimester) 11.5* 13.125
uptake (%)
DSS—current pathway 78.7* 66.225
DSS—NIPT pathway 78.7† 66.2†
NIPT after ≥1/150 risk (NIPT pathway) 72.5‡ 72.5‡
NIPT after 1/151-1/1000 risk (NIPT pathway) 70.5‡ 70.5‡
NIPT after ≥1/150 risk—no direct IPD 91.0‡ 91.0‡
IPD after positive screening (current pathway) 54.0‡ 54.0‡
Directly to IPD after ≥1/150 risk (NIPT pathway) 20.0‡ 20.0‡
IPD after positive NIPT 80.4* 80.4*
test outcomes (%)
Women with DSS risk ≥1/150 2.7* 2.3§
Women with DSS risk 1/151-1/500 3.2* 3.4§
Women with DSS risk 1/151-1/1000 7.1* 7.5§
NIPT positive if both DSS ≥1/150 and accepted NIPT 4.0‡ 4.0‡
NIPT positive if both DSS 1/151-1/500 and accepted NIPT 0.38¶ 0.38¶
NIPT positive if both DSS 1/151-1/1000 and accepted NIPT 0.25¶ 0.25¶
NIPT positive if both DSS ≥1/150 and accepted NIPT—no direct IPD 7.9‡ 7.9‡
NIPT repeat test 1.2* 1.2*
IPD positive if accepted IPD (current pathway) 10.1‡ 10.1‡
IPD positive if accepted IPD after positive NIPT 90.1* 90.1*
IPD positive—directly to IPD ≥1/150 (NIPT pathway) 21.9‡ 21.9‡
IPD related miscarriage 0.536 0.536
Costs (£)
Combined test 27.5237 27.5237
Quadruple test 37.2037 37.2037
NIPT
Laboratory costs NIPT** 250* 250*
Costs midwife for counselling and feedback 15.9638 15.9638
Costs phlebotomy and sending in sample 939 939
Cost of invasive test†† 650* 650*
Two separate analyses were undertaken, one using RAPID data and second using national data to estimate performance for whole country. Where RAPID 
data were not available, national data were used and vice versa.
DSS=Down’s syndrome screening; IPD=invasive prenatal diagnosis; NIPT=non-invasive prenatal testing.
*Data taken directly from RAPID study.
†Uptake of screening in RAPID clinics was slightly lower during RAPID study than before NIPT was offered (76.0% v 78.7%). Analysis assumed that 
screening uptake would not change because of NIPT.
‡Modelled figures based on RAPID data, national prevalence, and maternal age distribution of England and Wales.
§Age standardised rates for 2011 reference population.
¶National data, because numbers in RAPID study were too low to give reliable results.
**Includes labour, DNA extraction, quality control, library preparation, HiSeq reagents, plasticware, symphony service contract, HiSeq service contract, 
Qiacube service contract, 20% consumables VAT, 15% repeat/failure rate, and freezer storage costs.
††Weighted mean unit cost of chorionic villus sampling/quantitative fluorescence-polymerase chain reaction and amniocentesis/full karyotype reported 
by eight participating units, including pre-test counselling, consultant obstetrician time to perform procedure, cytogenetic laboratory costs, and 
post-test feedback and counselling.
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We used this to calculate 95% credible intervals for each 
model output. We also calculated costs and conse-
quences separately for one stop (where NIPT occurs on 
the same day as Down’s syndrome screening) and two 
stop clinics.
Patient involvement
Patients and the public are represented in the RAPID 
programme through the involvement of Genetic Alli-
ance UK and the patient support charity Antenatal 
Results and Choices (ARC), which supports women 
undergoing prenatal testing. The director of ARC was 
a co-applicant on the funding application for the 
study reported here and involved in the study design, 
conduct, analysis, and reporting. During the prepara-
tion for the study, patients and their partners were 
consulted on the format and content of the informa-
tion for patients to be used in the study. This was 
revised in the light of feedback from patients. The 
ARC director was involved in developing the educa-
tion packages for health professionals and assisted 
with training to ensure that health professionals 
understood the needs of expectant parents. Prelimi-
nary results of the study have already been presented 
at relevant annual meetings of lay groups. More 
details will be included on the RAPID website once 
the study is published. We have acknowledged the 
contribution of parents to the study. The study was 
designed to identify parents’ priorities, experience, 
and preferences in order to inform appropriate imple-
mentation into the clinical care pathway.
Results
sample characteristics and testing choices
During the study period, 40 527 pregnant women 
booked for maternity care at units participating in the 
study and 30 790 (76.0%) opted for Down’s syndrome 
screening. Overall, of the 3175 women with a current 
screening risk of at least 1/1000 from conventional 
screening, 2494 (78.6%) women accepted NIPT. Of 934 
women with a risk of at least 1/150, 695 (74.4%) 
accepted NIPT, and 1799 (80.3%) of 2241 with a risk of 
between 1/151 and 1/1000 accepted NIPT. The average 
gestation at which NIPT was performed was 14+2 
weeks. One hundred and ninety three (6%) women 
were lost to follow-up or miscarried: 129 in the 1/151-
1/1000 group and 64 in the higher risk group. Fifty 
nine (2.4%) results predicted aneuploidy (fig 1 ); 48 
(81%) of these were in pregnancies with risks of at 
least 1/150, and 11 (19%) were in the 1/151 to 1/1000 
group. There were 63 (2.5%) failed and 31 (1.2%) incon-
clusive results (fig 1). No abnormal results occurred in 
the failed NIPT group and three in the inconclusive 
group, two detected by repeat NIPT (one trisomy 21 
and one discordant trisomy 18) and the third (trisomy 
13) by amniocentesis following detection of sono-
graphic abnormalities.
Forty seven (80%) of the 59 women accepted confir-
matory invasive testing, which identified discordant 
results in five pregnancies (one Down’s syndrome, four 
trisomy 18), three in the high risk group and two in the 
intermediate risk group, and confirmed the abnormal-
ity in the other 42 pregnancies, 35 of which were termi-
nated and seven continued (fig 1 ). Two of the remaining 
12 women miscarried before making a decision, and 10 
(17%) women with a positive NIPT result declined inva-
sive testing. Two of these women had a termination of 
pregnancy without further testing. Reasons were not 
documented in one case, and ultrasound strongly indi-
cated trisomy 18 in the second. Eight women continued 
their pregnancies, with the abnormality confirmed in 
all eight after birth (fig 1). Of 42 pregnancies with a con-
firmed positive NIPT result for Down’s syndrome, 13 
(31%) of which were continued, 10 live births occurred. 
The average gestational age at the time invasive testing 
was offered following a positive NIPT result was 16 
weeks for both the high risk and intermediate risk 
groups, with 16 women having chorionic villus sam-
pling and 31 amniocentesis for confirmation of NIPT 
results. In the cohort accepting NIPT, the overall sensi-
tivity and specificity for NIPT in detecting aneuploidy, 
excluding the pregnancies in which no confirmation 
was available (two miscarriages and two terminations), 
was 100% (95% confidence interval 95% to 100%) and 
99.6% (99.1% to 99.9%) respectively. The positive pre-
dictive value was 92% (81% to 97%) overall—94% (83% 
to 99%) in the high risk group and 82% (48% to 98%) in 
the intermediate risk group.
One hundred and sixty six (17.8%) women with a 
standard screening risk of at least 1/150 opted for inva-
sive testing directly. Three (2%) invasive tests failed. 
The reasons for test failure are unknown; most com-
monly this is due to poor DNA quality or maternal blood 
contamination. In two cases, the invasive tests were 
repeated and found to be abnormal. In the third case, 
the mother opted for NIPT, which was normal. Fifty 
eight (35%) women with risks of at least 1/150 who 
chose direct invasive testing had abnormal results; one 
miscarried and 55 chose termination (fig 1). There were 
29 pregnancies with Down’s syndrome in this group, of 
which two (7%) continued and resulted in liveborn 
babies. This is substantially lower than the 13/42 (31%) 
who continued after an abnormal NIPT result 
(P=0.0003).
uptake
We predicted that 72.5% women with a risk of least 
1/150 would accept NIPT and 20% would opt for inva-
sive testing directly. Of all women with a positive NIPT 
result, 80.4% underwent subsequent confirmatory 
invasive testing. In units participating in the study, 
uptake of invasive testing before availability of NIPT 
was 54% in women with a risk of at least 1/150. Uptake 
of NIPT was not substantially different in one stop and 
two stop clinics. In the study, uptake of follow-on test-
ing overall (NIPT and invasive testing combined) in 
these women at high risk was 92.5%, higher than 
before availability of NIPT. For the scenario analysis, 
which does not allow direct invasive testing, the 
uptake of NIPT was 91%. In women with a lower 
screening risk (1/151 to 1/1000), the uptake of NIPT was 
predicted to be 70.5%.
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Costs and consequences of adding contingent niPt 
to current Down’s syndrome screening programme
Results were qualitatively similar with both sets of 
data (national data, RAPID data). Results using 
national data are described here, with the results 
using study data in appendix C. Table 3 gives the 
number of women expected to accept Down’s syn-
drome screening and subsequent NIPT or invasive 
testing, potential miscarriages, and the associated 
costs in a population of 698 500 pregnant women and 
show the effect of adding NIPT as a contingent test for 
standard screening risks of at least 1/150, 1/500, or 
1/1000 (see also fig 3 ). Use of NIPT as a contingent 
test with a risk threshold of 1/150 with the option of 
direct invasive testing resulted in a non-significant 
increase in the number of cases of Down’s syndrome 
detected by 195 (95% uncertainty interval −34 to 480) 
while requiring 3368 (2279 to 4027) fewer invasive 
tests and resulting in 17 (7 to 30) fewer procedure 
related miscarriages for a non-significant reduction 
in overall total costs (−£46 000, £−1 802 000 to 
£2 661 000) (table 4). Using the same screening 
threshold without the option of direct invasive test-
ing, we saw a slightly lower increase in Down’s syn-
drome cases detected by NIPT, but the reduction in 
invasive tests, and thus iatrogenic miscarriages, was 
greater, and the reduction in cost was maintained 
(tables 3 and 4; fig 3).
sensitivity analysis
Few parameters appreciably influenced the relative 
costs of a programme incorporating NIPT compared 
with current Down’s syndrome screening (moving NIPT 
from being cost saving to cost neutral; appendix C). At a 
screening threshold of 1/150 and allowing direct inva-
sive testing, the results of the analysis using national 
table 3 | Costs and outcomes of each pathway (in screening population of 698 500 pregnant women), using national data
testing strategy
screening niPt (£250) invasive testing total 
costs 
(£000)
Ds positive iPD related 
miscarriage 
(no)no
test 
positive £000 no £000
Direct 
no
after 
niPt no £000
niPt or 
iPD
Confirmed 
by iPD
Current 462 407 10 635 13 312 0 0 5743 0 3733 17 045 577 577 29
NIPT ≥1/1000 462 407 45 316 13 312 32 160 8940 2127 297 1576 23 829 833 732 12
NIPT ≥1/500 462 407 26 357 13 312 18 795 5225 2127 282 1566 20 103 814 719 12
NIPT ≥1/150 462 407 10 635 13 312 7711 2143 2127 248 1544 17 000 772 688 12
NIPT ≥1/1000—no direct IPD 462 407 45 316 13 312 34 128 9487 0 664 432 23 231 826 601 3
NIPT ≥1/500—no direct IPD 462 407 26 357 13 312 20 762 5772 0 649 422 19 506 807 587 3
NIPT ≥1/150—no direct IPD 462 407 10 635 13 312 9678 2690 0 615 400 16 403 765 556 3
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Fig 3 | benefits and costs of Down’s syndrome screening pathway nationally for current pathway and using non-invasive 
prenatal testing as contingent test for women with risk of ≥1/150, 1/500, and 1/1000. estimates are based on population 
of 698 000
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data would change from decreasing costs to increasing 
costs if the uptake of the current screening programme 
was 66.0% or lower, the uptake of Down’s syndrome 
screening with NIPT was 66.4% or higher, or the uptake 
of NIPT in women with a risk of at least 1/150 was 71.3% 
or lower.
varying uptake
We calculated the incremental costs of implementing 
NIPT at different uptake levels for NIPT and direct inva-
sive testing in high risk pregnancies. As uptake of NIPT 
and invasive testing are not independent, we used fig-
ures from study centres with the lowest and highest 
NIPT uptake and the lowest and highest overall uptake 
for NIPT and direct invasive testing combined (table 5). 
Using national data, when NIPT uptake was lowest 
(68.5%), invasive testing uptake was highest (25.9%) 
and incremental costs increased compared with the 
main analysis. Conversely, when NIPT uptake was high-
est (96.6%), direct invasive testing uptake was lowest 
(3.4%) and incremental costs decreased compared with 
the main analysis.
varying cost of niPt
Some uncertainty surrounds the test cost of NIPT, and 
the marginal costs of NIPT testing strategies versus cur-
rent screening are very sensitive to this. We calculated 
the incremental costs of implementing NIPT at different 
test costs of NIPT (fig 4) and determined the point at 
which it would be cost neutral. Using national data, at 
a screening threshold of 1/150, NIPT would be cost neu-
tral compared with current screening if the cost of NIPT 
was £256 with the option of direct invasive testing and 
£316 without this option (appendix C). At a screening 
threshold of 1/500, the values are £89 and £133; at 
1/1000, they are £42 and £71. As the threshold is 
reduced, the costs of NIPT must be lower and lower to 
remain cost neutral. Retaining the option of direct inva-
sive testing also necessitates a lower NIPT cost if the 
programme is to remain cost neutral.
We re-ran our analysis separately for data from one 
stop and two stop clinics, and the overall findings did 
not vary (appendix C).
discussion
Our results support the use of NIPT in our public sector 
Down’s syndrome screening pathway. Implementation 
as a contingent test at the current risk threshold of 1/150 
improves performance by significantly decreasing the 
false positive rate with a subsequent significant 
decrease in invasive tests needed and procedure related 
miscarriages. We found no significant effect on costs 
and an increase in the number of cases of Down’s syn-
drome cases detected. Lowering the risk threshold will 
increase the overall costs, while maintaining a signifi-
cant reduction in invasive testing and procedure related 
miscarriages, but with no significant further effect on 
Down’s syndrome cases detected (fig 3 ). Increasing the 
cost of NIPT—if, for example, a licence fee was needed 
in view of intellectual property considerations—would 
increase overall costs and alter the cost neutral point 
(fig 4 ). Furthermore, if a large proportion of women at 
high risk opt for direct invasive testing, as has been 
reported in units with a very high (98.2%) uptake of 
screening where 38% of high risk women opted for 
direct invasive testing,24  costs would also increase. 
table 4 | incremental costs and outcomes compared with current pathway (in screening population of 698 500 pregnant women), using national data
testing strategy
Per 698 500 pregnant women (95% uncertainty interval)
incremental Ds 
positive niPt or iPD
incremental Ds 
confirmed by iPD iPD avoided
iPD related 
miscarriage avoided
incremental costs* 
(£000)
NIPT ≥1/1000 256 (12 to 529) 155 (−137 to 446) 3319 (2436 to 4252) 16.6 (7.1 to 30.5) 6783 (824 to 17 096)
NIPT ≥1/500 237 (−10 to 557) 141 (−130 to 443) 3334 (2378 to 4225) 16.7 (7.1 to 30.8) 3058 (−482 to 8969)
NIPT ≥1/150 195 (−34 to 480) 111 (−135 to 356) 3368 (2779 to 4027) 16.8 (7.4 to 30.4) −46 (−1802 to 2661)
NIPT ≥1/1000—no direct IPD 249 (−12 to 511) 24 (−252 to 287) 5079 (4271 to 5901) 25.4 (11.5 to 45.4) 6186 (−210 to 16 983)
NIPT ≥1/500—no direct IPD 230 (−49 to 523) 10 (−254 to 280) 5094 (4273 to 5894) 25.5 (11.7 to 45.9) 2460 (−1565 to 8950)
NIPT ≥1/150—no direct IPD 187 (−52 to 427) −21 (−253 to 200) 5128 (4405 to 5881) 25.6 (11.7 to 46.2) −643 (−3025 to 2822)
DS=Down’s syndrome; IPD=invasive prenatal diagnosis; NIPT=non-invasive prenatal testing.
*At NIPT test costs £250.
table 5 | incremental costs compared with current pathway (in screening population of 698 500 pregnant women) for 
range of uptake values for non-invasive prenatal testing (niPt) and invasive prenatal diagnosis (iPD) in high risk 
pregnancies, using national data
scenario
uptake (%) incremental costs* (£000)
niPt iPD total 1/150 1/150—no direct iPD
Main analysis 72.5 20.0 91.0 −46 −643
Lowest NIPT uptake (Whittington Hospital NHS Trust) 68.5 25.9 94.4 235 −527
Highest NIPT uptake and highest total uptake (Salisbury NHS 
Foundation Trust)
96.6 3.4 100.0 −427 −337
Lowest total uptake (Barking, Havering and Redbridge University 
Hospitals NHS Trust)
74.5 13.9 88.5 −404 −728
Uptake figures were derived from table 1 but include trisomy 21 only.
*At NIPT test costs £250.
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As uptake of Down’s syndrome screening in our study 
(76%) was closer to the national average (66%),25 we 
suggest that uptake of direct invasive testing, if NIPT is 
implemented nationally with this option, is likely to be 
closer to the figure suggested from our data.
Additional benefits, not captured by the health eco-
nomic analysis, are linked to offering a test that women 
welcome as it increases confidence in results and 
reduces the need for invasive testing.33  Notably, approx-
imately one third of women with a confirmed positive 
NIPT result chose to continue their pregnancy, suggest-
ing that the high uptake of NIPT includes women who 
would like additional information for preparedness and 
not necessarily for decision making about termination 
of pregnancy. Although the numbers are small, this 
finding indicates that the birth rate of infants with 
Down’s syndrome may not change significantly if NIPT 
is introduced more widely, an observation in keeping 
with two regional US studies suggesting that NIPT has 
not affected the number of infants born with Down’s 
syndrome,4 41  as well as one UK study that also showed 
that some women continued the pregnancy with a diag-
nosis of Down’s syndrome after NIPT.24  In addition, 
NIPT can clearly be offered in the public sector without 
compromising informed choice. Analysis of decision 
making in a subset of women offered NIPT in our study 
(n=585) showed that rates of informed choice were high 
(89%),42  but this may reflect the effort made to educate 
all health professionals before the start of the study and 
the increased time spent counselling women.32  Further 
assessment is therefore needed to explore whether this 
high rate of informed choice can be maintained outside 
a research setting.42
The outcomes presented here, derived from uptake 
and outcome data collected in the RAPID study that are 
then modelled to reflect the effect nationally, are similar 
to those predicted from hypothetical scenarios using 
entirely modelled data,9 except that offering NIPT to 
women with risks of 1/150 or greater increases rather 
than decreases detection of Down’s syndrome when 
modelled data are used. This is a reflection of the 
increased uptake (>90%) of further testing (NIPT or 
direct invasive testing) in the NIPT pathways compared 
with the current pathway (54%), thus increasing detec-
tion of Down’s syndrome cases in the 1/150 or greater 
group as NIPT has a very high sensitivity.
Procedure related miscarriages are further decreased 
if invasive testing is offered only after a positive NIPT 
result. However, many people advocate allowing direct 
access to invasive testing for women at very high risk or 
those with abnormal ultrasound findings.26  Of note, in 
women with a risk of at least 1/150, 58 (34.9%) abnor-
malities were seen in the 166 women choosing direct 
invasive testing compared with 45/695 (6.5%) in those 
choosing NIPT, reflecting the fact that those choosing 
direct invasive testing are at higher risk, an average of 
1/8 compared with the average risk of 1/30 in those 
choosing NIPT. In the study. NIPT was offered to women 
with a screening result of at least 1/1000, allowing eval-
uation of behaviour relating to choice and the effect of 
using lower risk thresholds of 1/500 and 1/1000 to show 
that these would lead to slightly more positive results 
but increased costs compared with the current pathway. 
For introduction of NIPT to be cost neutral in these sce-
narios, the laboratory cost of NIPT would need to fall 
substantially (fig 3).
strengths and limitations of study
The main strength of our analysis was that we used 
actual clinical data, collected in a fully funded public 
sector maternity care system in units with a range of 
screening uptakes and modes of service delivery. These 
results thus reflect women’s behaviour in real life 
regarding uptake of Down’s syndrome screening, NIPT, 
and invasive testing as inputs for our model.
Limitations include the fact that data might not be 
nationally representative as they were collected in 
only eight hospitals. The proportion of women with a 
Down’s syndrome screening risk of at least 1/150 was 
higher than the current national figure, and the 
 number of women with a risk between 1/151 and 1/500 
or 1/1000 was lower. However, re-analysis using age 
standardised study data and national Down’s syn-
drome screening figures showed similar trends. Fur-
thermore, uptake of Down’s syndrome screening is 
around 66% nationally,25  compared with >75% in 
study clinics before the start of the study. In addition, 
the uptake of screening during the study fell slightly 
overall, possibly because women accessed commer-
cial NIPT and subsequently declined screening when 
booking for NHS maternity care. As a result, uncer-
tainty exists about whether introducing NIPT would 
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change screening uptake, so we assumed that it was 
unchanged. Furthermore, as women with a risk of at 
least 1/150 could opt directly for invasive testing with-
out undergoing NIPT first, we assumed that they 
would accept NIPT if this was the only available 
option. Thus we believe that our estimate based on 
women undergoing further testing (NIPT or direct 
invasive testing) is representative for the uptake of 
NIPT in this scenario. These findings are relevant to 
settings with well established Down’s syndrome 
screening programmes, as in the United Kingdom. For 
countries where these are not established, where atti-
tudes to screening and diagnosis vary, or where the 
geography is such that women do not have access to 
expert ultrasonography, alternative implementation 
strategies may be more appropriate.5 43 44
A further limitation of the economic analysis is the 
uncertainty surrounding the cost of NIPT. To overcome 
this, we present results for a range of values, taking as 
our base case a value of £250, which is the cost in our 
laboratory. Our economic analysis takes a narrower 
costing perspective than one that is commonly used in 
UK economic evaluations (NHS and personal social 
services perspective), reflecting the costs incurred by 
the UK National Screening Committee, which delivers 
the Down’s syndrome screening programme and 
which will decide whether to implement NIPT. Finally, 
NIPT can detect trisomies 13 and 18, but we have not 
analysed this in detail in our study, as screening for 
these conditions was not yet implemented in all par-
ticipating units. Further evaluation in a larger popula-
tion will be needed to draw meaningful conclusions, 
but most of these other trisomies (23/35) in the study 
occurred in those women at high risk who opted 
directly for invasive testing. This is probably because 
these conditions are usually associated with other 
sonographic anomalies.45  Of note, other chromosomal 
rearrangements, including the case of triploidy in our 
study, will not be detected using the method we report 
and women must be made aware of that limitation, 
particularly in the presence of fetal sonographic 
abnormalities.46
Conclusions
Using empirical data on uptake of testing, we have 
shown that NIPT can be provided effectively, and with-
out increasing costs, as part of a publicly funded 
national Down’s syndrome screening pathway with the 
provision of NIPT testing in a public sector laboratory. 
In view of the small number of discordant results, we 
concur with other authors that this has to be consid-
ered a highly sensitive screening test and that invasive 
testing will be needed for confirmation. We have also 
shown that some women will use NIPT for information 
only to prepare themselves for the birth of a baby with 
Down’s syndrome, so maternity services must have 
coordinated pathways for these families, including 
close monitoring in late pregnancy, and Down’s syn-
drome live birth rates may not change significantly. We 
conclude that a strong case exists for implementation 
of NIPT as part of the Down’s syndrome screening 
 programme to improve the quality of care for pregnant 
women and the performance of the programme as a 
whole. These data were presented to the UK National 
Screening Committee as part of its evidence review. 
The committee considered our findings before going to 
public consultation on its recommendation for NHS 
implementation of NIPT as a contingent test for all 
women with a traditional Down’s syndrome screening 
risk of at least 1/150. Subsequent to this consultation, 
the committee has recommended to the government 
that NIPT be implemented and is now awaiting minis-
terial decisions.
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